p(HGNC:ATXN3, var("?"))

Entity

Name

ATXN3

Namespace

hgnc

Namespace Version

20180906

Namespace URL

https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns

It also removed cellular aggregates of mutant Htt and improved motor performance in a mouse model of HD, reduced α-synuclein aggregation and afforded neuroprotection in a lesion-based model of PD and depleted mutant ataxin 3 in a mouse model of supraspinal cerebellar ataxia type 3 (REFS133,138,139) . PubMed:30116051

Another DUB known to be mutated in familial neurodegenerative diseases is Ataxin-3 in the polyglutamine (polyQ) spinocerebellar ataxia type 3 (Kawaguchi et al., 1994). PubMed:23528736

Early studies demonstrated that overexpression of a specific human HSP70 (HSPA1L) in a Drosophila disease model suppressed neurodegeneration associated with expression of polyQ-containing forms of both ataxin 3 or androgen receptor, and α -synuclein (Warrick et al., 1999; Chan et al., 2000, 2002; Auluck et al., 2002). PubMed:27491084

Another DUB known to be mutated in familial neurodegenerative diseases is Ataxin-3 in the polyglutamine (polyQ) spinocerebellar ataxia type 3 (Kawaguchi et al., 1994). PubMed:23528736

Early studies demonstrated that overexpression of a specific human HSP70 (HSPA1L) in a Drosophila disease model suppressed neurodegeneration associated with expression of polyQ-containing forms of both ataxin 3 or androgen receptor, and α -synuclein (Warrick et al., 1999; Chan et al., 2000, 2002; Auluck et al., 2002). PubMed:27491084